November 24, 2023 is a Friday,...................................... ................................................................. ................................................................. ................................................................. .............
Yuansheng saw a particularly enlightening point of view last night: the overall valuation of stocks on the main board, GEM and Science and Technology Innovation Board is on the high side. Therefore, in recent years, except for hot stocks, other stocks have almost not risen. To put it bluntly, unless they are hot stocks, most other stocks will not rise and will fall very easily. Fighting in this stock market is a bit like being in the F pit. Whoever enters will get... ................................................................. ................................................................. ................................................................. ................................................................. .....................Although it sounds a little harsh, it makes sense. Among A-shares, except for the North Exchange, which is a value depression, it is a pure land. In addition, other sectors have more stocks that are arbitrage................................. .....................
Therefore, smart people are now fighting in the Beijing Exchange...................... ..................................................
Yesterday, Yuansheng discovered a good stock through review, which is Eryao stock. Please look at its subject matter---------------------------------
The company's main business is the R&D, production and sales of advanced pharmaceutical intermediates, APIs and related products. The main product categories include anti-allergic, anti-thrombotic, antioxidant, gastric ulcer, anti-viral, antipyretic and analgesic products. pain relievers and UV absorbers, etc. The company's main products are pranlukast, sarpogrelate hydrochloride, 4-hydroxycoumarin, resveratrol, mosapride, celecoxib, biphenyl diester, dibenzoylresorcinol, etc. Advanced pharmaceutical intermediates and related products of specialty APIs have the characteristics of relatively complex structures, difficult research and development, high technical barriers, unique production processes, and high added value. The company's core management team has more than 20 years of industry experience and has accumulated rich R&D technology and industrial chain resources. The company has established long-term and stable cooperative relationships with downstream customers. The main product terminal markets are oriented to overseas markets such as South Korea and Japan. End customers Including well-known pharmaceutical companies such as South Korea's Daewoong Pharmaceutical, South Korea's CKD, South Korea's Idong Pharmaceutical, Japan's Sumitomo Pharmaceutical, Japan's Sanyo Chemical, and Japan's Nippon Medical Industries. Advanced pharmaceutical intermediates often require only one to two steps of chemical reaction to synthesize APIs. The company has pranlukast, sarpogrelate hydrochloride, ganciclovir, zaltoprofen, celecoxib, and epipilin hydrochloride. The company has obtained pharmaceutical production licenses for statin, azinamide and other products; the company's ganciclovir raw material has obtained the GMP certificate from the State Food and Drug Administration, and mosapride, celecoxib, itopride and biphenyl diester have Cooperating with Korean end-use raw material pharmaceutical manufacturers to complete the registration of Korean raw material pharmaceuticals, the company and its subsidiary Xiuyi Pharmaceutical obtained the foreign manufacturer certification certificate issued by the Japanese government. The company is a national high-tech enterprise with a complete and professional R&D platform, masters independent intellectual property rights and advanced production technology, and has 6 invention patents and 19 utility model patents. Since its establishment, the company has focused on main business development and technological innovation, and has been recognized as "Anhui Province Specialized and New Small and Medium-sized Enterprises", "Anhui Province Innovative Pilot Enterprises", "Anhui Province Enterprise Technology Center" and "Chuzhou City Engineering Technology Research center". The company invested in the establishment of a holding subsidiary, Hangzhou Xiaobei, in September 2021, and began to lay out the CDMO business of chemical raw materials to create a one-stop service platform for CDMO. The company uses its professional R&D team and its rich technical experience accumulation in production process research and development, quality research, and safety research to gradually cultivate and develop the chemical raw material medicine CDMO business to further extend the industrial chain, expand the business model, and enhance the company's Competitiveness.
In the morning, Eryao stock opened 3.93% lower, Yuansheng is waiting......................
The stock price fluctuated for less than 1 minute, and Eryao stock retreated to 21.31 yuan. Yuansheng bought it decisively, and finally controlled the cost at 21.95 yuan and ended the first battle of opening up new territories.
